DOP2012000245A - Composiciones sólidas - Google Patents

Composiciones sólidas

Info

Publication number
DOP2012000245A
DOP2012000245A DO2012000245A DO2012000245A DOP2012000245A DO P2012000245 A DOP2012000245 A DO P2012000245A DO 2012000245 A DO2012000245 A DO 2012000245A DO 2012000245 A DO2012000245 A DO 2012000245A DO P2012000245 A DOP2012000245 A DO P2012000245A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutically acceptable
solid compositions
dispersion
compound
hydrophylic polymer
Prior art date
Application number
DO2012000245A
Other languages
English (en)
Inventor
Bernd Liepold
Karin Rosenblatt
Rajeev Gokhale
Leena Prasad
Jonathan Miller
Eric A Schmitt
John B Morris
Peter Holig
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of DOP2012000245A publication Critical patent/DOP2012000245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSICIONES SÓLIDAS QUE COMPRENDEN EL COMPUESTO I AMORFO. UNA DISPERSIÓN SÓLIDA DE LA PRESENTE INVENCIÓN TAMBIÉN CONTIENE UN POLÍMERO HIDROFÍLICO FARMACÉUTICAMENTE ACEPTABLE Y UN AGENTE TENSIOACTIVO FARMACÉUTICAMENTE ACEPTABLE. EL COMPUESTO I PUEDE FORMULARSE EN UNA DISPERSIÓN SÓLIDA AMORFA QUE COMPRENDE UN POLÍMERO HIDROFÍLICO FARMACÉUTICAMENTE ACEPTABLE, Y PREFERIBLEMENTE UN AGENTE TENSIOACTIVO FARMACÉUTICAMENTE ACEPTABLE.
DO2012000245A 2010-03-10 2012-09-07 Composiciones sólidas DOP2012000245A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10

Publications (1)

Publication Number Publication Date
DOP2012000245A true DOP2012000245A (es) 2013-02-15

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000245A DOP2012000245A (es) 2010-03-10 2012-09-07 Composiciones sólidas

Country Status (28)

Country Link
US (1) US20110312973A1 (es)
EP (1) EP2544689B1 (es)
JP (2) JP5717768B2 (es)
KR (1) KR101579079B1 (es)
CN (2) CN104771364B (es)
AR (1) AR081736A1 (es)
AU (1) AU2011224558B2 (es)
BR (1) BR112012022774A2 (es)
CA (1) CA2792601C (es)
CL (1) CL2012002500A1 (es)
CO (1) CO6640208A2 (es)
DO (1) DOP2012000245A (es)
EA (1) EA021570B1 (es)
EC (1) ECSP12012148A (es)
ES (1) ES2613608T3 (es)
GT (1) GT201200257A (es)
IL (1) IL221833A (es)
MX (1) MX2012010478A (es)
MY (1) MY156888A (es)
NZ (1) NZ602288A (es)
PE (1) PE20130198A1 (es)
PH (1) PH12012501784A1 (es)
SG (1) SG183985A1 (es)
TW (1) TWI490218B (es)
UA (1) UA104517C2 (es)
UY (1) UY33265A (es)
WO (1) WO2011112558A2 (es)
ZA (1) ZA201207093B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678148B2 (ja) 1983-12-27 1994-10-05 北海製罐株式会社 缶胴ブランクの選別装置
ES2801678T3 (es) * 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Formulaciones de rifaximina y sus usos
KR20140003521A (ko) * 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US20130072528A1 (en) * 2011-09-16 2013-03-21 Abbvie Inc. Methods for Treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
DE112012002748T5 (de) * 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2015100283B4 (en) * 2011-10-21 2015-06-18 Abbvie Ireland Unlimited Company Methods for treating HCV
ES2572355B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de aad para uso en el tratamiento del vhc
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP2015522022A (ja) 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
NZ630435A (en) * 2012-07-12 2016-11-25 Abbvie Inc Crystalline forms of an hcv inhibitor
WO2014043208A1 (en) * 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
EP3016651A1 (en) 2013-07-02 2016-05-11 AbbVie Inc. Methods for treating hcv
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2015084953A1 (en) 2013-12-04 2015-06-11 Abbvie Inc. Crystal forms
EP3089757A1 (en) * 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
EP3157569B1 (en) * 2014-06-18 2019-07-24 F.Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
TWI630922B (zh) * 2015-08-28 2018-08-01 康霈生技股份有限公司 用於減少局部脂肪的醫藥組成物及其用途
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
IL300825A (en) 2017-03-15 2023-04-01 Cerecin Inc Pharmaceutical preparations with a high drug load of medium-length triglyceride chains and methods related thereto
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
SMT202400521T1 (it) * 2018-11-30 2025-01-14 Chemocentryx Inc Formulazioni di capsula
JP7825954B2 (ja) * 2020-08-26 2026-03-09 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4479092A4 (en) * 2022-02-14 2026-03-04 Purdue Research Foundation POLYMERIC SALTS INTENDED TO IMPROVE THE ADMINISTRATION OF MEDICATION FROM AMORPHIC SOLID DISPERSIONS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MXPA05010338A (es) * 2003-04-02 2005-11-17 Boehringer Ingelheim Int Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c.
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
ATE533473T1 (de) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
AR054122A1 (es) * 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
MX2010006659A (es) * 2007-12-21 2010-07-05 Hoffmann La Roche Proceso para la preparacion de un macrociclo.
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2732777A1 (en) * 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
EA021570B1 (ru) 2015-07-30
CN104771364A (zh) 2015-07-15
JP2015145387A (ja) 2015-08-13
JP5890553B2 (ja) 2016-03-22
ECSP12012148A (es) 2012-10-30
CO6640208A2 (es) 2013-03-22
MX2012010478A (es) 2013-02-01
US20110312973A1 (en) 2011-12-22
PH12012501784A1 (en) 2022-10-05
UY33265A (es) 2011-10-31
EP2544689A2 (en) 2013-01-16
CA2792601A1 (en) 2011-09-15
PE20130198A1 (es) 2013-03-24
JP5717768B2 (ja) 2015-05-13
EP2544689A4 (en) 2014-04-02
SG183985A1 (en) 2012-10-30
JP2013522208A (ja) 2013-06-13
CA2792601C (en) 2015-09-29
AU2011224558A1 (en) 2012-09-27
KR101579079B1 (ko) 2015-12-21
CN104771364B (zh) 2018-05-25
TWI490218B (zh) 2015-07-01
IL221833A (en) 2017-01-31
CN103118681A (zh) 2013-05-22
WO2011112558A3 (en) 2012-01-05
UA104517C2 (uk) 2014-02-10
AR081736A1 (es) 2012-10-17
EA201290892A1 (ru) 2013-03-29
EP2544689B1 (en) 2017-01-11
CL2012002500A1 (es) 2012-12-07
ZA201207093B (en) 2013-05-29
TW201202239A (en) 2012-01-16
CN103118681B (zh) 2015-02-18
WO2011112558A2 (en) 2011-09-15
AU2011224558B2 (en) 2014-02-27
NZ602288A (en) 2014-02-28
ES2613608T3 (es) 2017-05-24
MY156888A (en) 2016-04-15
GT201200257A (es) 2014-09-26
BR112012022774A2 (pt) 2017-09-12
KR20130048210A (ko) 2013-05-09

Similar Documents

Publication Publication Date Title
DOP2012000245A (es) Composiciones sólidas
UY33446A (es) Composiciones solidas
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
MX375444B (es) Composiciones sinergicas que comprenden una cepa de bacillus subtilis y un bioplaguicida.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2013001493A (es) Composiciones orales que comprenden un compuesto de cinc y un agente anti-microbiano.
PH12013501312A1 (en) Fluid compositions comprising a structuring agent
MX377288B (es) Composiciones sinérgicas que comprenden una cepa de bacillus subtilis y un pesticida.
GT201200276A (es) Combinaciones de compuestos activos
PH12016500793A1 (en) Turmeric extract containing soft pastilles
PH12016501034A1 (en) Oral care compositions and methods
MX2015009620A (es) Composiciones de copolímeros de alfa olefinas de alta viscocidad y métodos para elaborar y usar las mismas.
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
MX344189B (es) Formulaciones de mazindol.
WO2012139074A3 (en) Migrastatins and uses thereof
AR093813A1 (es) Composiciones en suspension de finafloxacina
MY154024A (en) Oral care compositions and methods
CR20120632A (es) Composiciones sòlidas
CR20130631A (es) Composiciones sòlidas
WO2012018958A3 (en) Ethanol compositions
WO2008090850A1 (ja) 抗癌剤の効果増強剤
MX2017014998A (es) Uso de hidroxido de potasio en el tratamiento de la queratosis actinica.
UA56181U (ru) Средство «суппозитории с дибамком» в форме ректальных суппозиториев для лечения эпилепсии
PH12014501092B1 (en) 5,5-dimethyl-2-propyl-hexahydro-2,4a-methanonaphthalene-1-one as a fragrance agent